Fundraising Fox
NorthLinks Bio
St Andrews, GB · 1 known investors
Find your way into NorthLinks Bio
Sign up to see every warm intro you have to NorthLinks Bio
- Paths you didn't know you had: your email and LinkedIn already hold routes to the NorthLinks Bio team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
NorthLinks Bio is a clinical-stage biopharmaceutical company developing HEX17, an intranasal antiviral designed to prevent respiratory virus infections by blocking viral entry at the nasal epithelium. The company targets broad protection against multiple respiratory viruses through a strain-independent mechanism.
Founders & leadership
FC
Fanny CavaliéChief Executive OfficerShe has over 20 years of experience in biotech and healthcare across multiple therapeutic areas, with background in building teams and operationalizing strategies from discovery through commercialization.
Investors · 1
RA Capitallisted by RA CapitalBoston
How we know: RA Capital's portfolio page · funding news · press coverage · Not right? Tell us
In the news
Frequently asked questions
- What does NorthLinks Bio do?
- NorthLinks Bio is a clinical-stage biopharmaceutical company developing HEX17, an intranasal antiviral designed to prevent respiratory virus infections by blocking viral entry at the nasal epithelium. The company targets broad protection against multiple respiratory viruses through a strain-independent mechanism.
- Who are NorthLinks Bio's investors?
- NorthLinks Bio's investors include RA Capital.
- Where is NorthLinks Bio headquartered?
- NorthLinks Bio is headquartered in St Andrews, GB.